Obicetrapib slashes LDL cholesterol by over 30% in high-risk heart patients
A large multinational trial published in the New England Journal of Medicine shows that obicetrapib significantly lowers LDL cholesterol in high-risk cardiovascular patients. The CETP inhibitor also improved key lipid…